Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. 2015

Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Recent investigations support that an anti-aging protein, namely Klotho, protects neurons against the oxidative stress and demyelination. We evaluated the protein concentration of Klotho and total anti-oxidant capacity (TAC) in the cerebrospinal fluid (CSF) of patients with relapsing-remitting multiple sclerosis (RRMS). Klotho concentration and TAC were significantly lower in patients as compared to controls. Klotho values showed a significant negative correlation with expanded disability status scale (EDSS). Moreover, a significantly positive correlation between TAC levels and Klotho concentrations was detected. Klotho may play an important role in the pathogenesis of MS, at least in part, through the regulation of redox system.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D005966 Glucuronidase Endo-beta-D-Glucuronidase,Endoglucuronidase,Exo-beta-D-Glucuronidase,beta-Glucuronidase,Endo beta D Glucuronidase,Exo beta D Glucuronidase,beta Glucuronidase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090265 Klotho Proteins Membrane bound glucuronidase enzymes that may play a role in activation of FIBROBLAST GROWTH FACTORS, and in the regulation of a variety of cell signaling pathways. alpha-Klotho Proteins,beta-Klotho Proteins,alpha Klotho Proteins,beta Klotho Proteins
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D020529 Multiple Sclerosis, Relapsing-Remitting The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914) Multiple Sclerosis, Acute Relapsing,Relapsing-Remitting Multiple Sclerosis,Acute Relapsing Multiple Sclerosis,Remitting-Relapsing Multiple Sclerosis,Multiple Sclerosis, Relapsing Remitting,Multiple Sclerosis, Remitting-Relapsing,Relapsing Remitting Multiple Sclerosis,Remitting Relapsing Multiple Sclerosis

Related Publications

Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
April 2000, Journal of neuroimmunology,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
April 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
August 2022, Journal of the neurological sciences,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
June 1998, Multiple sclerosis (Houndmills, Basingstoke, England),
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
April 1992, Annals of the New York Academy of Sciences,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
September 2013, Journal of neuroimmunology,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
January 2012, Journal of neuroimmunology,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
October 1997, Journal of neurology, neurosurgery, and psychiatry,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
September 2018, Prostaglandins & other lipid mediators,
Mohammad Sajad Emami Aleagha, and Bahaadin Siroos, and Mona Ahmadi, and Mohammad Balood, and Alireza Palangi, and Afsaneh Nazari Haghighi, and Mohammad Hossein Harirchian
October 2002, Neuroscience letters,
Copied contents to your clipboard!